AI assistant
ADHERIUM LIMITED — M&A Activity 2021
Jun 6, 2021
64305_rns_2021-06-06_add9b0a5-78c5-4d39-a264-2b4e7a11afa2.pdf
M&A Activity
Open in viewerOpens in your device viewer
==> picture [211 x 52] intentionally omitted <==
Adherium responds to Respiri announcement
Melbourne, Australia – 7 June 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, released a Directors' Statement on 10 May 2021 regarding the takeover proposed by Respiri Ltd. Adherium notes the announcement by Respiri on 3 June 2021 (“RSH announcement”) attempting to address some of the statements made in the Adherium Directors’ Statement.
Adherium is pleased to note, based on its feedback to Respiri, the amendments to the Respiri Bidder’s Statement removing the statement that its “wheezo” product immediately qualifies for Remote Patient Monitoring CPT reimbursement.
The Adherium Directors will respond to the RSH announcement and other ongoing inaccuracies via Adherium’s Target’s Statement, which will be sent directly to Adherium shareholders after receiving Respiri’s notice of despatch of the Bidder’s Statement.
The Adherium Directors continue to recommend that shareholders REJECT the Respiri offer by taking NO ACTION .
This ASX announcement was approved and authorised for release by the Board of Adherium.
About Adherium (ASX: ADR)
Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium’s Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD.
Adherium has a series of new asthma and COPD sensors in development which, with their existing capabilities, will also enable the capture of physiological measures enabling access to CPT reimbursement for remote patient monitoring in the US.
Adherium Limited (ACN 605 352 510) Collins Square, Tower 4, Level 18, 727 Collins Street Melbourne VIC 3000 Australia www.adherium.com | www.hailie.com | [email protected]
==> picture [211 x 52] intentionally omitted <==
These tools ultimately enable patients, with their physicians, to more effectively manage their Asthma and COPD and at the same time potentially deliver significant healthcare cost savings to payors and providers.
Learn more at adherium.com
Enquiries: Rudi Michelson Adherium Monsoon Communications [email protected] +61 3 9620 3333 +61 (0)411 402 737 [email protected]
Adherium Limited (ACN 605 352 510) Collins Square, Tower 4, Level 18, 727 Collins Street Melbourne VIC 3000 Australia www.adherium.com | www.hailie.com | [email protected]